Analysts Anticipate AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Will Announce Earnings of -$0.07 Per Share
Analysts forecast that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce earnings per share (EPS) of ($0.07) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for AcelRx Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.09). AcelRx Pharmaceuticals posted earnings of ($0.16) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 56.3%. The business is expected to report its next quarterly earnings results on Wednesday, November 4th.
On average, analysts expect that AcelRx Pharmaceuticals will report full-year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.51) to ($0.39). For the next financial year, analysts expect that the business will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.45) to ($0.17). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Monday, August 10th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $2.92 million for the quarter, compared to analyst estimates of $3.90 million.
Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in shares of AcelRx Pharmaceuticals by 5.7% in the 1st quarter. Geode Capital Management LLC now owns 1,153,393 shares of the specialty pharmaceutical company’s stock valued at $1,361,000 after acquiring an additional 62,709 shares during the period. BlackRock Inc. boosted its holdings in shares of AcelRx Pharmaceuticals by 0.9% in the 1st quarter. BlackRock Inc. now owns 5,659,788 shares of the specialty pharmaceutical company’s stock valued at $6,678,000 after buying an additional 47,771 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter valued at approximately $48,000. Wells Fargo & Company MN boosted its holdings in shares of AcelRx Pharmaceuticals by 19.4% in the 1st quarter. Wells Fargo & Company MN now owns 215,809 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 35,003 shares during the last quarter. Finally, State Street Corp lifted its holdings in AcelRx Pharmaceuticals by 2.5% during the 1st quarter. State Street Corp now owns 1,420,595 shares of the specialty pharmaceutical company’s stock valued at $1,676,000 after purchasing an additional 34,790 shares during the last quarter. Institutional investors own 19.45% of the company’s stock.
ACRX stock opened at $1.22 on Wednesday. The stock has a market cap of $113.81 million, a P/E ratio of -1.97 and a beta of 1.86. The firm has a 50 day simple moving average of $1.22 and a 200 day simple moving average of $1.27. AcelRx Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $2.80.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Read More: Trading based on a resistance level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.